The effect of pentaglobin in the treatment of critically ill patients with COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150107020592N27

Enrollment

Registered

2020-06-15

Start date

2020-03-20

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. covid19 disease

Interventions

Intervention group: patient under pentaglobin treatment: Patients who have acute respiratory failure due to covid-19 and do not respond to antiretroviral therapy due to the unknown nature of the disea

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Covid patients Patients over 18 years Non-intubated patients

Exclusion criteria

Exclusion criteria: Patients with dissatisfaction

Design outcomes

Primary

Measure	Time frame
Improve oxygenation. Timepoint: 0,1,2,3,7after treatment with cyclosporin. Method of measurement: Pulse oximeter.;Improve ct scan. Timepoint: Seven days after treatment. Method of measurement: CT scan unit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad Reza Hashemian

Shahid Beheshti University of Medical Sciences

smrhashemian@sbmu.ac.ir+98 912 111 9279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026